U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb has issued a statement announcing the agency’s Plant and Animal Biotechnology Innovation Action Plan. Gottlieb describes the plan as identifying priorities in three areas: (i) “advancing human and animal health by promoting product innovation and applying modern, efficient and risk-based regulatory pathways;” (ii) “strengthening public outreach and communication regarding the FDA’s approach to innovative plant and animal biotechnology;” and (iii) “increasing engagement with domestic and international partners on biotechnology issues.” The plan indicates that FDA will “adopt a comprehensive policy framework for the development and regulatory oversight of animal biotechnology products, including for intentionally genetically altered animals and the food and drug products derived from them.” The statement also announced that the agency’s Center for Veterinary Medicine will host a webinar on genome editing in animals on December 3, 2018.

About The Author

For decades, manufacturers, distributors and retailers at every link in the food chain have come to Shook, Hardy & Bacon to partner with a legal team that understands the issues they face in today's evolving food production industry. Shook attorneys work with some of the world's largest food, beverage and agribusiness companies to establish preventative measures, conduct internal audits, develop public relations strategies, and advance tort reform initiatives.